GLORIOSA

About this trial

Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate (ADC). It received accelerated FDA approval in November 2022 for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, orprimary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens. FRα, also known as folate receptor 1 (FOLR1), has limited expression on normal tissues but is elevated in most ovarian cancers,which makes it an attractive target for the development of novel therapies.
The GLORIOSA trial will evaluate maintenance therapy with MIRV + bevacizumab vs. bevacizumab alone in patients with FRα-high recurrent platinum sensitive ovarian cancer (rPSOC), who demonstrated CR, partial response (PR), or stable disease (SD) following 2nd Line triplet therapy.

Patient Profile

Patients with FRα-high recurrent platinum sensitive ovarian cancer who have received prior platinum based chemotherapy plus bevacizumab.

Where’s this trial being run?

Beaumont Hospital, Bon Secours Cork, Cork University Hospital, Sligo University Hospital, St James’s Hospital, University Hospital Galway, and University Hospital Waterford

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	GLORIOSA
Number:	22-18
Full Title:	Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Principal Investigator:	Prof. Patrick Morris
Type:	Industry Sponsored
Sponsor:	Immunogen
Recruitment Started:	Global: Feb 2024 Ireland: Nov 2024

Global Recruitment Target:	418
Ireland Recruitment Target:	20